We are delighted to welcome André Løvestam as the new CEO of Age Labs. André is a seasoned leader with over twenty years of CEO experience driving international growth in consumer goods, IT and tech companies, both listed and private. Since joining Age Labs in May, André has played a pivotal role in strategy, business development, and partnering, significantly contributing to our mission while enabling our founding team to intensify their focus on scientific research and delivery.
Handing over the reins to André, Karl Trygve Kalleberg will transition to the role of Chief Scientific Officer, and Arne Søraas will step into the position of Chief Medical Officer. Furthermore, Age Labs strengthens the Board by adding two new members; Einar Brummenæs, current CEO of Abelee, and Jan Fikkan, former general manager of GE Healthcare in Japan and the Nordics. These strategic improvements position us for future innovations in the fields of epigenetic diagnostics and sophisticated biological age measurement.
André comments: “I am both excited and humbled to lead Age Labs on its mission to improve healthcare with advanced epigenetic biomarker diagnostics for age-related diseases. Our robust pipeline of epigenetic biomarkers, proprietary EPIPHANY biomarker discovery platform, unique access to biosamples with longitudinal data, and my colleagues’ outstanding competence and talent, position us to develop into a 'biomarker factory’. Age Labs represents a deeply meaningful opportunity for me to contribute to people living healthier for longer."
Karl Trygve adds: “André has unlocked new opportunities for Age Labs and has been an inspiration from day 1. This strategic appointment marks a significant milestone in Age Labs' journey towards commercializing biomarkers for early detection of age-related diseases and drug response prediction.”